StartGLTO • NASDAQ
add
Galecto Inc
Seneste lukkekurs
5,09 $
Dagsinterval
4,70 $ - 5,10 $
Årsinterval
4,40 $ - 23,50 $
Markedsværdi
6,28 mio. USD
Gns. volumen
18,93 t
P/E-værdi
-
Udbytteprocent
-
Primær børs
NASDAQ
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | sep. 2024info | År til år-ændring |
---|---|---|
Indtægt | — | — |
Driftsudgifter | 3,84 mio. | -34,42 % |
Nettoindtægt | -3,88 mio. | 52,27 % |
Overskudsgrad | — | — |
Earnings per share | -3,39 | 32,03 % |
EBITDA | -3,83 mio. | 32,07 % |
Effektiv afgiftssats | -0,18 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | sep. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 19,68 mio. | -55,46 % |
Samlede aktiver | 23,38 mio. | -53,29 % |
Samlede passiver | 2,44 mio. | -80,73 % |
Samlet egenkapital | 20,94 mio. | — |
Shares outstanding | 1,32 mio. | — |
Kurs/indre værdi | 0,30 | — |
Afkast af aktiver | -37,89 % | — |
Afkast af kapital | -43,02 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | sep. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | -3,88 mio. | 52,27 % |
Pengestrøm fra drift | -3,65 mio. | 56,81 % |
Pengestrøm fra investering | 0,00 | -100,00 % |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | -3,18 mio. | -2.709,84 % |
Fri pengestrøm | -2,08 mio. | 44,50 % |
Om
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Administrerende direktør
Grundlagt
2011
Hovedkvarter
Website
Ansatte
13